As of Feb 27
| -0.12 / -1.81%|
The 2 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 9.00. The median estimate represents a +53.61% increase from the last price of 6.51.
The current consensus among 3 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.